Prostate-specific membrane antigen cars and methods of use thereof
The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
1. A modified T cell, comprising:
a chimeric antigen receptor (CAR) having affinity for a prostate specific membrane antigen (PSMA) on a target cell, wherein the CAR comprises the amino acid sequence set forth in SEQ ID NO:105; and
a dominant negative receptor consisting of the amino acid sequence set forth in SEQ ID NO:115.
2. The modified T cell of claim 1 , wherein the modified T cell is derived from a human.
3. The modified T cell of claim 1 , wherein the modified T cell is an autologous cell.